A Phase III randomized open-label study of izalontamab brengitecan (BMS-986507) with osimertinib versus osimertinib alone or with platinum-based chemotherapy as first-line therapy in EGFR-mutant locally advanced or metastatic non-small cell lung cancer
Sponsor: Bristol-Myers Squibb Services Unlimited Company
Phase: 3
Disease: EGFR-mutant non-small cell lung cancer, Non-squamous non-small cell lung carcinoma
EU trial number: 2026-526486-21-00
Population: Adults aged at least 18 with previously untreated non-squamous locally advanced stage IIIB/IIIC or metastatic/recurrent stage IVA/IVB NSCLC harboring sensitizing EGFR exon 19 deletion or exon 21 L858R mutation, measurable disease and ECOG performance status 0–1.
Register Investigator Interest
Interested in offering this trial to suitable patients?